[On the decongesting effect of the novel imidazole derivative N-(2-imidazolin-2-yl)-N-(4-indanyl)amine (indanazoline) (author's transl)].
In 35 test persons with normal nasal condition the newly developed imidazole derivative 2-(2-imidazolin-2-yl)-N-(4-indanyl)amine hydrochloride (indanazoline E-VA-16, active principle of Farial) was tested for its decongesting influence on nasal mucosa and for its tolerability using anterior rhinomanometric techniques and comparing the results with those of xylometazoline. 10 min after application of either drug the stream volume increased significantly thus evidencing decongestion of the nasal mucosa. There was no substantial difference between the two substances. 8 h after application the initial values were virtually reached again in both treated groups. Since indanazoline showed little effect in conditions of minor respiratory resistance but was highly effective against increased initial respiratory resistance it is concluded that its therapeutic safety margin might be larger. The reactive hyperemia observed after both drugs should not be overvalued. Blood pressure and pulse rate were not appreciably influenced at any time. Both drugs were well tolerated.
D000403:Airway Resistance / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D014663:Nasal Decongestants / Q000009:adverse effects / Q000494:pharmacology*; D009297:Nasal Mucosa / Q000187:drug effects
D007093:Imidazoles; D014663:Nasal Decongestants; C027634:indanazoline; C009695:xylometazoline
Uber dei schleimhautabschwellende Wirkung des neuartigen Imidazolderivates N-(2-Imidazolin-2-yl)-N-(4-indanyl)amin (Indanazolin).